Literature DB >> 25911084

Extreme hypercholesterolemia presenting with pseudohyponatremia - a case report and review of the literature.

Iram Hussain1, Zahid Ahmad1, Abhimanyu Garg2.   

Abstract

Pseudohyponatremia has been reported in association with severe hypertriglyceridemia and hyperparaproteinemia, but its association with severe hypercholesterolemia is not well-known. We report a 43-year-old woman with refractory primary biliary cirrhosis who presented with asymptomatic hyponatremia (121 mmol/L; normal range: 135-145 mmol/L). She was ultimately found to have a total serum cholesterol level of 2415 mg/dL (normal range: 120-199 mg/dL) - secondary to accumulation of lipoprotein-X-causing pseudohyponatremia. The diagnosis was confirmed by measurement of serum osmolality (296 mOsm/kg H2O; normal range: 270-300 mOsm/kg H2O) and serum sodium by direct potentiometry (141 mmol/L). Furthermore, following 16 sessions of plasmapheresis over a 4-month period, there was marked lowering of serum cholesterol to 200 mg/dL and normalization of serum sodium (139 mmol/L) as measured by indirect potentiometry. This case shows that extreme hypercholesterolemia from elevation of lipoprotein-X particles in cholestasis can be a rare cause of pseudohyponatremia. It highlights the need to measure serum sodium with direct potentiometry in the setting of extreme hypercholesterolemia and consider this possibility before initiating treatment of hyponatremia. Published by Elsevier Inc.

Entities:  

Keywords:  Cholestasis; Hypercholesterolemia; Hyponatremia; Lipoprotein-X (LpX); Primary biliary cirrhosis (PBC); Pseudohypokalemia; Pseudohyponatremia

Mesh:

Substances:

Year:  2014        PMID: 25911084     DOI: 10.1016/j.jacl.2014.11.007

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  10 in total

Review 1.  Hyponatraemia - presentations and management.

Authors:  Rosemary Dineen; Christopher J Thompson; Mark Sherlock
Journal:  Clin Med (Lond)       Date:  2017-06       Impact factor: 2.659

Review 2.  Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise.

Authors:  G Liamis; T D Filippatos; A Liontos; M S Elisaf
Journal:  Hepatol Int       Date:  2016-06-21       Impact factor: 6.047

Review 3.  Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications.

Authors:  Katriina Nemes; Fredrik Åberg; Helena Gylling; Helena Isoniemi
Journal:  World J Hepatol       Date:  2016-08-08

4.  Pseudohyponatraemia secondary to hyperlipidaemia in obstructive jaundice.

Authors:  Samuel O Igbinedion; Sudha Pandit; Meher S Mavuram; Moheb Boktor
Journal:  BMJ Case Rep       Date:  2017-12-01

5.  PSEUDOHYPONATREMIA IN THE SETTING OF HYPERCHOLESTEROLEMIA.

Authors:  Lea El Hage; Edmunds Reineks; Christian Nasr
Journal:  AACE Clin Case Rep       Date:  2018-11-01

6.  Detection of Lipoprotein X (LpX): A challenge in patients with severe hypercholesterolaemia.

Authors:  Agnieszka Ćwiklińska; Agnieszka Mickiewicz; Robert Kowalski; Barbara Kortas-Stempak; Agnieszka Kuchta; Krzysztof Mucha; Michał Makowiecki; Anna Gliwińska; Krzysztof Lewandowski; Leszek Pączek; Marcin Fijałkowski; Marcin Gruchała; Maciej Jankowski
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

7.  Primary biliary cholangitis presenting as acute ischemic stroke: A rare association.

Authors:  Bumsoo Park; Sumaiya Islam; Raghavendra C Vemulapalli; Maria E Shreve
Journal:  Clin Case Rep       Date:  2020-01-04

8.  Effect of postoperative early enteral nutrition on clinical outcomes and immune function of cholangiocarcinoma patients with malignant obstructive jaundice.

Authors:  Bing-Qiang Ma; Shi-Yong Chen; Ze-Bin Jiang; Biao Wu; Yu He; Xin-Xin Wang; Yuan Li; Peng Gao; Xiao-Jun Yang
Journal:  World J Gastroenterol       Date:  2020-12-14       Impact factor: 5.742

9.  Case report: Unusual and extremely severe lipoprotein X-mediated hypercholesterolemia in extrahepatic pediatric cholestasis.

Authors:  Rossella Colantuono; Chiara Pavanello; Andrea Pietrobattista; Marta Turri; Paola Francalanci; Marco Spada; Pietro Vajro; Laura Calabresi; Claudia Mandato
Journal:  Front Pediatr       Date:  2022-08-04       Impact factor: 3.569

10.  Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia--efficacy, safety, and pharmacokinetics.

Authors:  Biff F Palmer; Amy D Rock; Emily J Woodward
Journal:  Drug Des Devel Ther       Date:  2016-01-18       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.